The study evaluates BCG and intravesical gemcitabine in high-grade non-muscle invasive bladder cancer patients previously exposed to BCG. Preliminary results show a 94% complete response rate at six ...

“With the Expanded Access Program, it is an opportunity for patients to receive the drug in real-world practice,” says Sarah P. Psutka, MD, MSc. In this video, Sarah P. Psutka, MD, MSc, highlights the ...

Increased public interest in vaginal estrogen can enhance patient-physician discussions and enable earlier symptom management for post-menopausal women. Disparities in access to vaginal estrogen are ...

HIFU achieved noninferior STFS outcomes compared to radical prostatectomy, with 90% vs 86% of patients free from subsequent treatment at 30 months. HIFU demonstrated better functional outcomes, with ...

“It encompasses and contains the miTNM, PROMISE, PRIMARY, RECIP, PSMA-RADS, and E-PSMA concept and criteria all together,” says Jeremie Calais, MD, PhD. In this video, Jeremie Calais, MD, PhD, ...

“One of the goals of this study was to look at whether 24-hour urine testing in the VA population included all the important components of 24-hour urine panel testing,” says Ryan Hsi, MD, FACS.

ProstACT GLOBAL assesses 177Lu-TLX591 plus standard care in metastatic castration-resistant prostate cancer. The study uses PSMA-targeted radionuclide with lutetium 177, focusing on external ...

The EAP seeks to generate real-world data on cretostimogene for BCG-unresponsive NMIBC, targeting diverse patient populations lacking access to FDA-approved treatments. Cretostimogene has shown ...

Aquablation therapy shows high efficacy in reducing medication dependency and surgical retreatment rates for benign prostatic hyperplasia. The precision of Aquablation minimizes side effects by ...

Belzutifan is recommended for approval in the EU for advanced RCC and VHL disease-associated tumors, with a decision expected in Q1 2025. In the LITESPARK-005 trial, belzutifan showed superior ...

PSMA-PET imaging is essential for staging, monitoring, and treatment decisions in prostate cancer but has limitations like false positives. Low-volume lesions and benign conditions, such as Paget's ...

TAR-200 is an intravesical gemcitabine-releasing system for BCG-unresponsive NMIBC, evaluated in the SunRISe-1 trial. The trial's focus was on TAR-200 monotherapy, with other cohorts including ...